An issue of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) bonds rose 1.1% as a percentage of their face value during trading on Monday. The high-yield issue of debt has a 2.95% coupon and is set to mature on December 18, 2022. The debt is now trading at $93.25 and was trading at $92.09 one week ago. Price changes in a company’s bonds in credit markets often predict parallel changes in its share price.

Several research analysts have weighed in on TEVA shares. Barclays set a $20.00 price target on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Thursday, May 24th. Citigroup set a $25.00 price target on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Thursday, May 31st. Wells Fargo & Co raised Teva Pharmaceutical Industries from an “underperform” rating to a “market perform” rating in a research report on Monday, June 18th. Goldman Sachs Group boosted their price target on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Monday, June 25th. Finally, Zacks Investment Research raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $27.00 price target on the stock in a research report on Monday, July 9th. Seven equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $21.03.

Shares of NYSE TEVA traded up $0.58 during midday trading on Monday, hitting $23.43. 29,324,300 shares of the company’s stock were exchanged, compared to its average volume of 12,916,044. The company has a current ratio of 1.03, a quick ratio of 0.69 and a debt-to-equity ratio of 1.86. Teva Pharmaceutical Industries Ltd has a 12 month low of $10.85 and a 12 month high of $25.96. The company has a market capitalization of $22.57 billion, a P/E ratio of 6.10, a P/E/G ratio of 2.77 and a beta of 0.69.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Thursday, August 2nd. The company reported $0.78 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.14. The company had revenue of $4.70 billion during the quarter, compared to the consensus estimate of $4.75 billion. Teva Pharmaceutical Industries had a positive return on equity of 19.92% and a negative net margin of 47.98%. The firm’s revenue for the quarter was down 17.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.02 EPS. analysts predict that Teva Pharmaceutical Industries Ltd will post 2.67 EPS for the current fiscal year.

In other news, EVP Sven Dethlefs purchased 2,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 3rd. The stock was acquired at an average cost of $21.92 per share, for a total transaction of $43,840.00. Following the purchase, the executive vice president now directly owns 6,445 shares of the company’s stock, valued at approximately $141,274.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Iris Beck Codner sold 4,165 shares of the business’s stock in a transaction on Thursday, August 9th. The shares were sold at an average price of $22.70, for a total value of $94,545.50. Following the completion of the sale, the executive vice president now owns 8,290 shares of the company’s stock, valued at $188,183. The disclosure for this sale can be found here. Insiders own 0.43% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Global Financial Private Capital LLC boosted its stake in Teva Pharmaceutical Industries by 92.2% in the 2nd quarter. Global Financial Private Capital LLC now owns 23,632 shares of the company’s stock valued at $575,000 after purchasing an additional 11,335 shares during the period. Benjamin F. Edwards & Company Inc. boosted its stake in Teva Pharmaceutical Industries by 553.3% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 22,361 shares of the company’s stock valued at $544,000 after purchasing an additional 18,938 shares during the period. Sei Investments Co. boosted its stake in Teva Pharmaceutical Industries by 26.8% in the 2nd quarter. Sei Investments Co. now owns 162,241 shares of the company’s stock valued at $3,946,000 after purchasing an additional 34,305 shares during the period. Toronto Dominion Bank bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at $669,000. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in Teva Pharmaceutical Industries by 25.5% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 83,473 shares of the company’s stock valued at $2,030,000 after purchasing an additional 16,946 shares during the period. Institutional investors and hedge funds own 64.52% of the company’s stock.

About Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Read More: Risk Tolerance and Your Investment Decisions

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.